| Literature DB >> 33621918 |
Junpeng Xu1, Qingge Jia2, Yan Zhang3, Yuan Yuan1, Tianqi Xu1, Kangjie Yu1, Jia Chai1, Kaijing Wang1, Ligang Chen4, Tian Xiao5, Mingyang Li6.
Abstract
RSK4 refers to one Ser/Thr protein kinase functioning downstream pertaining to the signaling channel of protein kinase (MAPK) stimulated by Ras/mitogen. RSK4 can regulate numerous substrates impacting cells' surviving state, growing processes and proliferating process. Thus, dysregulated RSK4 active state display a relationship to several carcinoma categories, covering breast carcinoma, esophageal squamous cell carcinoma, glioma, colorectal carcinoma, lung carcinoma, ovarian carcinoma, leukemia, endometrial carcinoma, and kidney carcinoma. Whether RSK4 is a tumor suppressor gene or one oncogene remains controversial. No specific inhibiting elements for RSK4 have been found. This review briefs the existing information regarding RSK4 activating process, the function and mechanism of RSK4 in different tumors, and the research progress and limitations of existing RSK inhibitors. RSK4 may be a potential target of molecular therapy medicine in the future.Entities:
Keywords: Cancer; Inhibitor; Ribosomal S6 kinase 4 (RSK4)
Year: 2021 PMID: 33621918 DOI: 10.1016/j.prp.2021.153374
Source DB: PubMed Journal: Pathol Res Pract ISSN: 0344-0338 Impact factor: 3.250